English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aim  To conduct an open‐label study to provide  UK  real‐world evidence regarding the use of insulin glargine 300 units/ml (U300) in people with Type 1 diabetes mellitus.    Methods  People with Type 1 diabetes who had been prescribed U300 ≥6 months before data collection and had HbA 1c  levels recorded within 3 months prior to U300 (baseline) were included. The primary endpoint was change in HbA 1c  from baseline to month 6 after U300 initiation. Other endpoints included number of documented hypoglycaemic and diabetic ketoacidosis episodes, and change in daily basal insulin dose.    Results  A total of 298 people with Type 1 diabetes were included [mean age 42.1 years, mean HbA 1c  79 mmol/mol (9.4%)]. After U300 initiation, the mean reduction in HbA 1c  from baseline to month 6 was –4 mmol/mol (–0.4%;  P <0.001;  n =188). The total daily basal insulin dose at 6 months was 1.3 units higher than at the time of U300 initiation ( P <0.001;  n =275) but was not significantly different from the prior basal insulin dose. There was no clinically significant difference in weight between baseline and month 6 [mean difference +0.7 kg, 95%  CI  –0.1, 1.5;  P =0.084;  n =115). During the 6 months before and after U300 initiation, severe hypoglycaemic episodes were documented for 6/298 and 4/298 participants. Diabetic ketoacidosis episodes requiring Accident and Emergency department visits or hospitalization were documented for 4/298 and 6/298 participants, before and after U300 initiation, respectively.    Conclusions  In people with Type 1 diabetes, a change in basal insulin to U300 was associated with clinically and statistically significant HbA 1c  improvements, without significant changes in basal insulin dose and weight. Documented severe hypoglycaemia episodes and diabetic ketoacidosis requiring Accident and Emergency department visits or hospitalization were low and similar before and after U300 initiation.

diabetic medicine

A multicentre,  UK , retrospective, observational study to assess the effectiveness of insulin glargine 300 units/ml in treating people with Type 1 diabetes mellitus in routine clinical practice ( SPARTA )